of conditions, as the Chinese claimed as long ago as 2737 BCE,1 with considerably fewer side effects for many people than other treatments.10 Marijuana could compete with established brand medications that are backed by powerful global economic, social and political forces and their legislative allies.

Thus there are at least 2 powerful obstacles to the decriminalization of marijuana, both arising from the vested interests that have grown up and taken hold under prohibition. Still, CMAJ is to be congratulated: better late than never.

Craig Jones
Research Associate
Queen’s Centre for Health Services and Policy Research
Queen’s University
Kingston, Ont.

References

I read with interest the recent CMAJ editorial on marijuana.1 The numerous contradictory reports on the effects of smoking marijuana can be easily clarified: marijuana is a crude herb that contains at least 10 psychotropics as well as several hundred long-chain hydrocarbons. Each “joint” has a different chemical makeup.

For the chemicals in marijuana to be approved as medications they would have to be tested by means of the traditional, and only legally approved, methodology: gas chromatographic analysis of the plant and mass spectrometry. Once all of the chemicals were isolated, a large amount of each chemical would have to be synthesized so the appropriate toxicological and pharmacological studies in animals could be carried out.

Jose Carranza
Associate Professor of Psychiatry
University of Texas Medical School
Houston, Tex.

Reference

As an emergency physician who spent 14 years in general practice in a rural area with lots of drug abuse, I am shocked at the ignorance of CMAJ’s editors concerning the health effects of marijuana use.1

To say that the effects of this substance are “mostly irrelevant” to the users is at the very least irresponsible. What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth? What about the serious amotivational syndromes in youth?

Mike Howlett
Chief of Emergency Medicine
Colchester Regional Hospital
Truro, NS

Reference
The Intergroup study appears to be the most significant to date that might justify a recommendation for chemohormonal therapy in postmenopausal patients with ER-positive tumours. Unfortunately the full report has not yet been published. It would be useful to know whether there were differential benefits in this study in women aged 50–59, 60–69 and more than 69 years, for making decisions concerning the adjuvant treatment of otherwise healthy people at risk of iatrogenic disease but also at varying risk of developing metastatic disease if not optimally treated.

I should appreciate the authors’ views on the use of chemotherapy, particularly in older women with ER-positive tumours, in light of these comments.

David Ginsburg
Professor of Oncology and Medicine
Queen’s University
Kingston, Ont.

References

The author responds:

David Ginsburg has conducted his own analysis of selected studies. The meta-analysis by the Early Breast Cancer Trials’ Collaborative Group, which included all the trials of chemotherapy plus tamoxifen versus tamoxifen alone in over 9000 postmenopausal women, demonstrated a statistically significant reduction in both breast cancer recurrence and mortality in favour of the combined chemohormonal therapy. Ginsburg points out that some of the trials that compared chemotherapy plus tamoxifen with tamoxifen alone included a small number of patients with estrogen receptor (ER)-negative tumours. Tamoxifen would not be expected to be of benefit in such patients. The implication is that the demonstrated benefit of combination therapy is driven by the effect of chemotherapy in the ER-negative patients. We believe that this is a spurious hypothesis for several reasons. First, the numbers of ER-negative patients were balanced between treatment arms in these trials and these patients comprised a relatively small subgroup. Second, chemotherapy is effective in women with ER-positive tumours as well as ER-negative tumours. Finally, in trials that included only postmenopausal women with ER-positive tumours, a benefit was detected in favour of the addition of chemotherapy to tamoxifen. For example, the Intergroup recently updated the results of their trial of anthracycline-containing chemotherapy plus tamoxifen versus tamoxifen alone. There was a statistically significant improvement in survival in favour of the addition of chemotherapy to tamoxifen.

We agree with Ginsburg that there were very few patients over 70 years of age in the trials of adjuvant chemotherapy. We alluded to this in our guideline1 and we feel that our recommendations were balanced and did not overstate the case.

Mark Levine
Professor
Departments of Medicine and Clinical Epidemiology and Biostatistics
McMaster University
Hamilton, Ont.

Ammoniation against malaria

The recent case series of malaria deaths in Canada illustrates the need for heightened awareness of tropical diseases by Canadian physicians. I was recently involved in caring for a patient who died of malaria shortly after returning from Kenya. Unfortunately, the patient had not taken antimalarial prophylaxis.

While I was in Africa I had the opportunity to see the use of 2 powerful antimalarial agents, dihydroartemisinin and β-artemeter. Studies have shown that these drugs are highly effective plasmodicides, even in multidrug-resistant malaria. The World

CMAJ • SEPT. 4, 2001; 165 (5) 527